Cargando…
Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials
PURPOSE: Considering the adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids for treating osteoarthritis (OA), development of drugs that are more effective and better tolerated than existing treatments is urgently needed. This systematic review aimed to evaluate the efficacy...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297056/ https://www.ncbi.nlm.nih.gov/pubmed/35900204 http://dx.doi.org/10.1530/EOR-21-0103 |
_version_ | 1784750399099502592 |
---|---|
author | Zhao, Di Zeng, Ling-feng Liang, Gui-hong Pan, Jian-ke Luo, Ming-hui Han, Yan-hong Liu, Jun Yang, Wei-yi |
author_facet | Zhao, Di Zeng, Ling-feng Liang, Gui-hong Pan, Jian-ke Luo, Ming-hui Han, Yan-hong Liu, Jun Yang, Wei-yi |
author_sort | Zhao, Di |
collection | PubMed |
description | PURPOSE: Considering the adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids for treating osteoarthritis (OA), development of drugs that are more effective and better tolerated than existing treatments is urgently needed. This systematic review aimed to evaluate the efficacy and safety of anti-nerve growth factor (NGF) monoclonal antibodies vs active comparator therapy, such as NSAIDs and oxycodone, in treating hip or knee OA. METHODS: Databases were comprehensively searched for randomized controlled trials (RCTs) published before January 2022. Efficacy and safety outcomes were assessed. RESULTS: Six RCTs that included 4325 patients were identified. Almost all the RCTs indicated that moderate doses of anti-NGF monoclonal antibody treatment significantly improved efficacy outcomes based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score, the WOMAC physical function score and the Patient’s Global Assessment compared with those of the active comparator. At least half of the RCTs indicated that the incidence of severe adverse events, withdrawals due to adverse events (AEs) and total joint replacement were not significantly different between anti-NGF monoclonal antibody treatment and active comparator therapy, but the outcomes of some studies may have been limited by a short duration of follow-up. Most RCTs suggested that anti-NGF monoclonal antibody treatment had a lower incidence of gastrointestinal and cardiovascular AEs. However, the majority of RCTs reported a higher incidence of abnormal peripheral sensation with anti-NGF monoclonal antibody treatment. Furthermore, the higher incidence of rapidly progressive osteoarthritis (RPOA) with anti-NGF monoclonal antibody treatment should also not be overlooked, and the identification of patient characteristics that increase the risk of RPOA is critical in further studies. CONCLUSION: Based on the current research evidence, anti-NGF monoclonal antibodies are not yet a replacement for analgesic drugs such as NSAIDs but might be a new treatment option for hip or knee OA patients who are intolerant or unresponsive to nonopioid or opioid treatment. Notably, however, considering the inconsistency and inconclusive evidence on the safety outcomes of recent studies, more research is needed, and long-term follow-up is required. |
format | Online Article Text |
id | pubmed-9297056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-92970562022-07-20 Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials Zhao, Di Zeng, Ling-feng Liang, Gui-hong Pan, Jian-ke Luo, Ming-hui Han, Yan-hong Liu, Jun Yang, Wei-yi EFORT Open Rev General Orthopaedics PURPOSE: Considering the adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids for treating osteoarthritis (OA), development of drugs that are more effective and better tolerated than existing treatments is urgently needed. This systematic review aimed to evaluate the efficacy and safety of anti-nerve growth factor (NGF) monoclonal antibodies vs active comparator therapy, such as NSAIDs and oxycodone, in treating hip or knee OA. METHODS: Databases were comprehensively searched for randomized controlled trials (RCTs) published before January 2022. Efficacy and safety outcomes were assessed. RESULTS: Six RCTs that included 4325 patients were identified. Almost all the RCTs indicated that moderate doses of anti-NGF monoclonal antibody treatment significantly improved efficacy outcomes based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score, the WOMAC physical function score and the Patient’s Global Assessment compared with those of the active comparator. At least half of the RCTs indicated that the incidence of severe adverse events, withdrawals due to adverse events (AEs) and total joint replacement were not significantly different between anti-NGF monoclonal antibody treatment and active comparator therapy, but the outcomes of some studies may have been limited by a short duration of follow-up. Most RCTs suggested that anti-NGF monoclonal antibody treatment had a lower incidence of gastrointestinal and cardiovascular AEs. However, the majority of RCTs reported a higher incidence of abnormal peripheral sensation with anti-NGF monoclonal antibody treatment. Furthermore, the higher incidence of rapidly progressive osteoarthritis (RPOA) with anti-NGF monoclonal antibody treatment should also not be overlooked, and the identification of patient characteristics that increase the risk of RPOA is critical in further studies. CONCLUSION: Based on the current research evidence, anti-NGF monoclonal antibodies are not yet a replacement for analgesic drugs such as NSAIDs but might be a new treatment option for hip or knee OA patients who are intolerant or unresponsive to nonopioid or opioid treatment. Notably, however, considering the inconsistency and inconclusive evidence on the safety outcomes of recent studies, more research is needed, and long-term follow-up is required. Bioscientifica Ltd 2022-07-05 /pmc/articles/PMC9297056/ /pubmed/35900204 http://dx.doi.org/10.1530/EOR-21-0103 Text en © The authors https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | General Orthopaedics Zhao, Di Zeng, Ling-feng Liang, Gui-hong Pan, Jian-ke Luo, Ming-hui Han, Yan-hong Liu, Jun Yang, Wei-yi Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials |
title | Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials |
title_full | Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials |
title_fullStr | Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials |
title_full_unstemmed | Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials |
title_short | Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials |
title_sort | does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? a systematic review of randomized controlled trials |
topic | General Orthopaedics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297056/ https://www.ncbi.nlm.nih.gov/pubmed/35900204 http://dx.doi.org/10.1530/EOR-21-0103 |
work_keys_str_mv | AT zhaodi doesantinervegrowthfactormonoclonalantibodytreatmenthavethepotentialtoreplacenonsteroidalantiinflammatorydrugsandopioidsintreatinghiporkneeosteoarthritisasystematicreviewofrandomizedcontrolledtrials AT zenglingfeng doesantinervegrowthfactormonoclonalantibodytreatmenthavethepotentialtoreplacenonsteroidalantiinflammatorydrugsandopioidsintreatinghiporkneeosteoarthritisasystematicreviewofrandomizedcontrolledtrials AT liangguihong doesantinervegrowthfactormonoclonalantibodytreatmenthavethepotentialtoreplacenonsteroidalantiinflammatorydrugsandopioidsintreatinghiporkneeosteoarthritisasystematicreviewofrandomizedcontrolledtrials AT panjianke doesantinervegrowthfactormonoclonalantibodytreatmenthavethepotentialtoreplacenonsteroidalantiinflammatorydrugsandopioidsintreatinghiporkneeosteoarthritisasystematicreviewofrandomizedcontrolledtrials AT luominghui doesantinervegrowthfactormonoclonalantibodytreatmenthavethepotentialtoreplacenonsteroidalantiinflammatorydrugsandopioidsintreatinghiporkneeosteoarthritisasystematicreviewofrandomizedcontrolledtrials AT hanyanhong doesantinervegrowthfactormonoclonalantibodytreatmenthavethepotentialtoreplacenonsteroidalantiinflammatorydrugsandopioidsintreatinghiporkneeosteoarthritisasystematicreviewofrandomizedcontrolledtrials AT liujun doesantinervegrowthfactormonoclonalantibodytreatmenthavethepotentialtoreplacenonsteroidalantiinflammatorydrugsandopioidsintreatinghiporkneeosteoarthritisasystematicreviewofrandomizedcontrolledtrials AT yangweiyi doesantinervegrowthfactormonoclonalantibodytreatmenthavethepotentialtoreplacenonsteroidalantiinflammatorydrugsandopioidsintreatinghiporkneeosteoarthritisasystematicreviewofrandomizedcontrolledtrials |